BILL SUMMARY
2nd Session of the 60th Legislature

Bill No.:	**HB3834**
Version:	**INT**
Request Number:	**15886**
Author:	**Rep. May**
Date:	**2/10/2026**
Impact:	**See Analysis Below**

Research Analysis

HB 3834, as introduced, creates the "Oklahoma Breakthrough Therapy Act," which requires an ibogaine drug developer to provide certain information before the State Department of Health may contract with them. The Department must also negotiate a contract with the drug developer that requires the developer to match the state's investment in clinical trials, to provide specified reporting, to establish a plan to ensure broad and accessible ibogaine treatment access following approval by the United States Food and Drug Administration, and to provide a plan to recognize the state's economic interest in the intellectual property generated over the clinical trials. The Department may also make additional terms and reasonable deviations in negotiating a contract provided the contract is fair and creates at least a substantially equivalent value for the state.

The drug developer must prepare and submit a quarterly report to the State Department of Health and the Department must annually submit a report to the Legislature by Dec. 1 each year until the clinical trials are finished. The measure requires the ibogaine intellectual property account to be created in the Office of the State Treasurer. Expenditures from this account will only be used for programs or research benefitting at-risk populations that suffer from conditions treatable with ibogaine. Medical professionals licensed in the state will not be subject to adverse licensing action for recommending psilocybin or ibogaine therapy services.

Prepared By: Suzie Nahach, House Research Staff

Fiscal Analysis

HB 3834 creates the Oklahoma Breakthrough Therapy Act, which sets requirements for drug developers prior to entering into any contractual agreement with the State Department of Health (OSDH). The measure requires drug developers to submit quarterly reports to OSDH and OSDH to provide annual reports to the Legislature until clinical trials are complete.

According to OSDH, the fiscal impact of the proposed bill depends on the level of engagement with the drug developer. If involvement is minimal, such as providing space for clinical trials, the cost would be negligible. However, if OSDH is required to share clinical trial expenses to secure FDA approval for ibogaine treatments, costs could escalate into the eight-figure range.

Prepared By: Alexandra Ladner, House Fiscal Staff

Other Considerations

None.